VIVUS Inc

VIVUS — Investor Presentation (January 2019)

24 slides from VIVUS's investor presentation, Jan 7, 2019

  1. Slide 1: Forward Looking Statements; Non-GAAP Financial Measures

    Forward Looking Statements Non-GAAP Financial Measures ©2018 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 2 Forward Looking Statements Certain statements in this presentation are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and are subje

  2. Slide 2: Contents

    Contents ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 3 •OverviewPage 4 •PharmaceuticalsPage 7 •AcquisitionsPage 14 •DebtPage 17 •FinancialsPage 19 •Strategic DevelopmentPage 21

  3. Slide 3: Brief Overview of Company

    Overview Brief Overview of Company HISTORY RESET GROWTH 1991 – Apr 30th, 2018 May 1st, 2018 – June 30th, 2018 – Hard Reset July 1st, 2018 – Future • Founded as sexual health biopharmaceutical and device company • IPO’ed in 1993 • Company had four products approved • Multiple CEO’s • Activist Shareho

  4. Slide 4: Investment Highlights

    Overview Investment Highlights This is the first quarter VIVUS generated positive EBITDA based on bond almost two years ahead of schedule performance, VIVUS expects to be able to address the remaining structured sales force QYSMIA ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 5

  5. Slide 5: Management Focus Next Months

    Overview Management Focus Next 24 Months ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 6 •Drive Qsymia revenue and profitability with the Transformative Pharmaceutical Operating Model •Re-launch PANCREAZE in Q1 2019 •New sales team and excellent market insights •Leverage the Tr

  6. Slide 6: Management Team

    Overview Management Team • McKesson, BMS, OTN, BVCF, ORIX, Willow • Johnson & Johnson, Novartis, KRIM, Willow • Deloitte and Touche, Alexza Pharmaceuticals, Pharmacyclics, Incyte, • Wilson, Sonsini, Goodrich and Rosati P.C. • Glaxo Smith Kline, ICC, Novartis • Elan, Merck, Schering Plough, Sanofi Av

  7. Slide 7: Pharmaceutical Assets

    Pharmaceuticals Pharmaceutical Assets Track and Breakthrough Therapy designation ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 8 Pre-Clinical Phase 1 Phase 2 Phase 3 Approved PANCREAZE® -EPI due to Cystic Fibrosis + other conditions Qsymia® -Obesity (Planned EU refiling based o

  8. Slide 8: Qsymia is a safe and effective therapy for BMI management

    Pharmaceuticals Qsymia is a safe and effective therapy for body mass index management Proprietary extended-release formulation combining low doses of active ingredients from two previously approved compounds, phentermine and topiramate We believe the 3-month data from our CONQUER study supports shor

  9. Slide 9: PANCREAZE for exocrine pancreatic insufficiency

    Pharmaceuticals • PANCREAZE is indicated for exocrine pancreatic insufficiency (EPI) due to cystic fibrosis or other conditions Pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreas glands Provides proven benefits to EPI patients Indicated for both pediat

  10. Slide 10: STENDRA for erectile dysfunction

    Pharmaceuticals • STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 11 Generics Market Due to Viagra and Cialis going off Patent US, South America, Canada and India Rights were sol

  11. Slide 11: VI-0106 PAH

    Pharmaceuticals VI-0106 PAH • Tacrolimus for the Treatment of Pulmonary Arterial Hypertension (PAH) ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 12 PAH is a serious, rare, and progressive disease Progressive narrowing in pulmonary arteries, resulting in right heart failure and

  12. Slide 12: PAH Clinical Overview

    Pharmaceuticals PAH Clinical Overview The progressive narrowing in pulmonary arteries leading to heart failure ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 13

  13. Slide 13: Worldwide Market for PAH Therapies

    VIVUS Pharmaceuticals Worldwide Market for PAH Therapies $4 500 $4 000 $3,500 $3,000 $2500 $2,.000 $1 500 $1,000 $500 $-Adempas Adcirca Revatio Opsun1.it Letairis Tracleer •orentiram •Tyvaso •Ren1odulin •ventavis Flolan 0.._', C/J Q ;.:= ..... ...... ] ::s ...... 2007 2008 2009 2010 2011 Year 2012 2

  14. Slide 14: Tacrolimus Experience in PAH patients

    Pharmaceuticals Tacrolimus Experience in PAH patients ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 15 •Compassionate use •3 end-stage patients, WHO functional class 3 and 4 •Positive impact on clinical outcomes •Dramatically reduced rate of hospitalizations •Functional class i

  15. Slide 15: Asset Acquisition Philosophy

    Acquisitions Asset Acquisition Philosophy ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 16 •As a core VIVUS activity, we are evaluating additional in-licensing and acquisition candidates that would meet our goals of meeting patients’ needs while working toward profitability and

  16. Slide 16: Corporate Debt Alternatives

    Debt Corporate Debt Alternatives ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 17 In order of current preference 1 Improve operating performance to generate enough recurring cash flow to pay down and refinance debt 2 Acquire asset(s) that generate $25M - $40M of annual non-GAAP

  17. Slide 17: Debt Bridge January 2019 to May 2020

    Debt Debt Bridge January 2019 to May 2020 $350 $300 Senior Debt $250 New Senior $200 Cash Used $150 $100 New Second Lien $50 Convertible Debt $0 $291.4M of Total Debt Nov 2018 $181.4M Pay Off Convertible Debt May 2020 $216.4M Total Debt May 31st 2020 • As of May 2020, based on current internal proje

  18. Slide 18: VIVUS Health Platform

    Strategic Development VIVUS HEALTH PLATFORM ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 19 • As part of the relaunch of Qsymia and PANCREAZE we intend to launch the VIVUS HEALTH PLATFORM • We believe that an integrated approach to weight management yields a higher percentage

  19. Slide 19: VIVUS Health Platform – Launching Q1 2019

    Strategic Development VIVUS HEALTH PLATFORM – Launching Q1 2019 Use Case Dependent NUTRITIONAL SCIENCE PHARMACEUTICAL SCIENCE Monitors PATIENT • • • • • • Sleep EKG Weight BMI BP Dietary Inputs ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 20

  20. Slide 20: VIVUS Health Platform – Why?

    Strategic Development VIVUS HEALTH PLATFORM – WHY? ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 21 • The VIVUS HEALTH PLATFORM will allow VIVUS to partner with MD’s, Dieticians, Nutritionists, Self Insured Employers, Private and Public Insurers and most importantly Patients to

  21. Slide 21: Financial Snapshot

    Financials Financial Snapshot (in $MM, except per share data) Company Name Ticker Current Share Price (1/2/2019) 52 Week High 52 Week Low Vivus, Inc VVUS $ $ $ 2.34 9.90 2.52 Plus: Debt (Principal value) Convertible Notes, due 2020 Senior Secured Notes, due 2024 Less Cash and Investments 190.0 110.0

  22. Slide 22: Operating Results

    Financials Operating Results 2017 Revenue: 2017 2018 Q4 Q1 Q2 Q3 LTM (in $MMs, except per share data) License and milestone revenue 7,500 - - - - - Royalty revenue 2,483 664 585 668 1,126 3,043 Operating expenses: Amortization of intangible asset 544 91 91 1,273 3,638 5,093 Selling and marketing 16,

  23. Slide 23: Management Focus Next Months

    Overview Management Focus Next 24 Months ©2019 VIVUS Inc. All rights reserved | www.vivus.com | Nasdaq: VVUS 24 •Drive Qsymia revenue and profitability with the Transformative Pharmaceutical Operating Model •Re-launch PANCREAZE in Q1 2019 •New sales team and excellent market insights •Leverage the T

  24. Slide 24: Thank You

    25 VIVUS Thank You ©2019 VIVUS Inc. llrightsreserved. INNOVATIVE THERAPIES-NOVEL PRODUCTS | wwrw.vivus.com | Nasdaq: WUS

Vivus — Investor Presentation (January 2019) on 6ix